Andrew A. Hindman - 20 May 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
SVP, CHIEF FINANCIAL OFFICER
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
20 May 2022
Net transactions value
-$29,410
Form type
4
Filing time
24 May 2022, 19:17:27 UTC
Previous filing
23 Feb 2022
Next filing
27 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Tax liability $29,410 -3,365 -0.7% $8.74 479,183 20 May 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
F2 Includes 1,263 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2022.